Financial giants have made a conspicuous bullish move on Madrigal Pharmaceuticals. Our analysis of options history for Madrigal Pharmaceuticals MDGL revealed 8 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $144,520, and 4 were calls, valued at $115,189.
What's The Price Target?
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $175.0 to $210.0 for Madrigal Pharmaceuticals over the recent three months.
Insights into Volume & Open Interest
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Madrigal Pharmaceuticals's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Madrigal Pharmaceuticals's substantial trades, within a strike price spectrum from $175.0 to $210.0 over the preceding 30 days.
Madrigal Pharmaceuticals Option Activity Analysis: Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MDGL | PUT | TRADE | BULLISH | 06/21/24 | $15.0 | $11.6 | $11.7 | $210.00 | $40.9K | 106 | 211 |
| MDGL | PUT | TRADE | BULLISH | 06/21/24 | $15.0 | $11.5 | $11.6 | $210.00 | $40.6K | 106 | 176 |
| MDGL | PUT | TRADE | BULLISH | 06/21/24 | $15.0 | $11.4 | $11.4 | $210.00 | $31.9K | 106 | 149 |
| MDGL | PUT | TRADE | BULLISH | 06/21/24 | $15.0 | $11.4 | $11.5 | $210.00 | $31.0K | 106 | 149 |
| MDGL | CALL | SWEEP | NEUTRAL | 07/19/24 | $22.7 | $17.3 | $19.92 | $210.00 | $29.9K | 4 | 30 |
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
In light of the recent options history for Madrigal Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Current Position of Madrigal Pharmaceuticals
- Currently trading with a volume of 190,187, the MDGL's price is down by -5.7%, now at $205.54.
- RSI readings suggest the stock is currently may be approaching oversold.
- Anticipated earnings release is in 90 days.
Expert Opinions on Madrigal Pharmaceuticals
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $150.0.
- In a cautious move, an analyst from B of A Securities downgraded its rating to Underperform, setting a price target of $150.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Madrigal Pharmaceuticals with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
